The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
Mesalazine is an established and recommended first-line treatment for mild-to-moderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor necrosis factor (TNF) agent is not clearly informed...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2024
|
| _version_ | 1817930745688096768 |
|---|---|
| author | Paridaens, K Freddi, MJ Travis, SPL |
| author_facet | Paridaens, K Freddi, MJ Travis, SPL |
| author_sort | Paridaens, K |
| collection | OXFORD |
| description | Mesalazine is an established and recommended first-line treatment for mild-to-moderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor necrosis factor (TNF) agent is not clearly informed from current guidelines. The use of mesalazine is supported by robust clinical evidence supporting its efficacy at inducing remission in patients with moderately active disease. A key advantage of mesalazine is its tolerability profile being similar to that of placebo, which contrasts with that of the corticosteroids and advanced therapies, where there is the potential for significant toxicities. Mesalazine also has cost advantages over anti-TNFs and other advanced therapies. Evidence supports the consideration of all patients with moderately active UC for first-line mesalazine therapy at an optimized dose of ≥4g/d (± 1g/d rectal). Patients responding to treatment within 2 weeks should continue at ≥4g/d for at least 6 months before a dose reduction is considered, since this then alters the pattern of disease. |
| first_indexed | 2024-09-25T04:09:51Z |
| format | Journal article |
| id | oxford-uuid:044f6efe-5f81-407b-855c-f19449c248fc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:11:01Z |
| publishDate | 2024 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:044f6efe-5f81-407b-855c-f19449c248fc2024-10-16T09:06:07ZThe continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:044f6efe-5f81-407b-855c-f19449c248fcEnglishJisc Publications RouterFrontiers Media2024Paridaens, KFreddi, MJTravis, SPLMesalazine is an established and recommended first-line treatment for mild-to-moderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor necrosis factor (TNF) agent is not clearly informed from current guidelines. The use of mesalazine is supported by robust clinical evidence supporting its efficacy at inducing remission in patients with moderately active disease. A key advantage of mesalazine is its tolerability profile being similar to that of placebo, which contrasts with that of the corticosteroids and advanced therapies, where there is the potential for significant toxicities. Mesalazine also has cost advantages over anti-TNFs and other advanced therapies. Evidence supports the consideration of all patients with moderately active UC for first-line mesalazine therapy at an optimized dose of ≥4g/d (± 1g/d rectal). Patients responding to treatment within 2 weeks should continue at ≥4g/d for at least 6 months before a dose reduction is considered, since this then alters the pattern of disease. |
| spellingShingle | Paridaens, K Freddi, MJ Travis, SPL The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title | The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title_full | The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title_fullStr | The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title_full_unstemmed | The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title_short | The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis |
| title_sort | continuing value of mesalazine as first line therapy for patients with moderately active ulcerative colitis |
| work_keys_str_mv | AT paridaensk thecontinuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis AT freddimj thecontinuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis AT travisspl thecontinuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis AT paridaensk continuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis AT freddimj continuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis AT travisspl continuingvalueofmesalazineasfirstlinetherapyforpatientswithmoderatelyactiveulcerativecolitis |